

~ Updates on HPMS Memos ~

<b>CMS Email Title &amp; Release Date</b>	VBID, Part D Payment Modernization, and Part D Senior Savings Models Webinar – Dated 3/20/2020
<b>Summary</b>	CMS announced a webinar scheduled for <b>March 24, 2020</b> to discuss the Value Based Insurance Design (VBID), Part D Payment Modernization, and Part D Senior Savings models. Questions can be submitted in advance as instructed in the email.
<b>Action</b>	Informational to PACE. Refer to the memo for details.
<b>CMS Email Title &amp; Release Date</b>	2020 HPMS Fiscal Soundness Module Release – Dated 3/20/2020
<b>Summary</b>	CMS released the 2020 HPMS Fiscal Soundness Module and will now accept 2019 audited annual financial statements and 2020 quarterly financial statements. Instructions related to completing submissions and uploading documentation can be found within HPMS.
<b>Action</b>	Applicable to PACE plans that have active contracts in contract year 2020. PACE plans must submit audited annual financial statements to CMS no later than 180 days after the organization’s fiscal year end. Refer to the memo for additional details.
<b>CMS Memo Title &amp; Release Date</b>	Part D Senior Savings Model Calendar Year 2021 Pharmaceutical Manufacturer Model Participation and Part D Sponsor – Dated 3/24/2020
<b>Summary</b>	CMS announced participating manufactures and provided additional information on sponsor requirements for the Part D Senior Savings Model for CY 2021. A link to a complete list of Model Drug NDCs is provided.
<b>Action</b>	Informational to PACE.
<b>CMS Memo Title &amp; Release Date</b>	Release of Encounter Data Report Cards Q4 2019 – Information – Dated 3/24/2020
<b>Summary</b>	CMS announced the availability of the Q4 2019 encounter data report cards, including technical notes about the methodology used in report card preparation, in HPMS.
<b>Action</b>	Informational to PACE. Refer to the memo for details on contents and the pathway to access the report cards.

<b>CMS Memo Title &amp; Release Date</b>	Continuation of the Prescription Drug Event (PDE) Reports and PDE Analysis Reporting Initiatives for the 2020 Benefit Year – Dated 3/24/2020
<b>Summary</b>	CMS announced the continuation of the PDE Reports and PDE Analysis initiatives for 2020 benefit year that support CMS’s efforts to improve the accuracy of PDE data. Information on the reports and the actions expected from participating sponsors is provided.
<b>Action</b>	Applicable to PACE. To add/change user authorization to access the PDE Analysis Reporting Web Portal, refer to the memo for additional details and instructions. Pharmastar can assist plans with the reports from the portal. Additionally, if your plan would like someone at Pharmastar to have access to the web portal, please reach out to your Client Support Specialist.
<b>CMS Memo Title &amp; Release Date</b>	Medicare Advantage/Prescription Drug System (MARx) April 2020 Payment – INFORMATION – Dated 3/27/2020
<b>Summary</b>	<p>CMS released information about the April payment which is scheduled for <b>April 1, 2020</b> and may require plan action on the following:</p> <ul style="list-style-type: none"> <li>• CY2018 Coverage Gap Discount (CGD) Reconciliation</li> <li>• Changes to the Batch Input Transaction Data File Name</li> <li>• Extension of the Transition Period for Submitting MARx Batch Input Header Record</li> </ul>
<b>Action</b>	Applicable to PACE. Refer to the memo for items that may be applicable to your plan.
<b>CMS Email Title &amp; Release Date</b>	Delay of 2020 Medicare Part C and Part D Reporting Requirements - Data Validation – Dated 3/28/2020
<b>Summary</b>	CMS has delayed the start of the data validation (DV) of the 2019 Part C and Part D Reporting Requirements data previously scheduled to begin on <b>Wednesday, April 1, 2020</b> . More information will be provided when the 2020 Data Validation web-based training becomes available.
<b>Action</b>	Informational to PACE as PACE is excluded from the Part C reporting requirements and waived of the Part D reporting requirements.
<b>CMS Memo Title &amp; Release Date</b>	Extended Implementation Date for Revised Integrated Denial Notice (Form CMS 10003-NDMCP) – Dated 3/30/2020
<b>Summary</b>	CMS has extended the implementation date for the Notice of Denial of Medical Coverage (or Payment) Form CMS-10003 (also known as the Integrated Denial Notice or IDN) due to minor changes to the notice. Plans should begin using the revised IDN as soon as possible, but no later than <b>May 15, 2020</b> .

<b>Action</b>	Informational to PACE.
<b>CMS Memo Title &amp; Release Date</b>	Reprioritization of PACE, Medicare Parts C and D Program, and Risk Adjustment Data Validation (RADV) Audit Activities – Dated 3/30/2020
<b>Summary</b>	Effective immediately, CMS is reprioritizing its scheduled program audits and suspending RADV activities related to the payment year 2015. The suspension of the audit activities mentioned are time-limited, and CMS will make an announcement when normal activities are resumed after the public health emergency has ended.
<b>Action</b>	Applicable to PACE. Refer to the memo for complete details.
<b>CMS Email Title &amp; Release Date</b>	Extended Resubmission Deadline for 2019 Part D Medication Therapy Management (MTM) Program Data – Dated 3/31/2020
<b>Summary</b>	CMS has extended the resubmission deadline for 2019 Part D MTM data per the Part D Reporting Requirements to <b>April 14, 2020 at 11:59 PM PT</b> . The resubmission deadline for all other Part C and D reporting sections remains <b>March 31, 2020</b> .
<b>Action</b>	Informational to PACE as PACE is excluded from the Part C reporting requirement and waived of the Part D reporting requirements.
<b>CMS Email Title &amp; Release Date</b>	Contract Year 2020 Integrated Denial Notice - Extended Implementation Date for Medicare-Medicaid Plans – Dated 3/31/2020
<b>Summary</b>	CMS has extended the implementation date of the form for MMPs to no later than <b>May 15, 2020</b> .
<b>Action</b>	Informational to PACE.
<b>CMS Email Title &amp; Release Date</b>	Coverage Gap Discount Program: April Participating Labeler Codes – Dated 4/1/2020
<b>Summary</b>	CMS will update the manufacturer labeler codes for the Coverage Gap Discount Program by <b>April 1, 2020</b> . The update includes the following to be added: <ul style="list-style-type: none"> <li>• 72495 Millicent U.S., Inc.</li> <li>• 42769 Bay Pharma, Inc.</li> </ul>
<b>Action</b>	Although the Coverage Gap Discount Program does not apply to PACE, the participating labeler codes are applicable because only brand name prescriptions with NDCs from these codes are accepted for Part D payment. Pharmastar has made the necessary software adjustments to accommodate for the updated codes.

<b>CMS Memo Title &amp; Release Date</b>	Reporting Update for Medicare-Medicaid Plans due to COVID-19– Dated 4/2/2020
<b>Summary</b>	Due to COVID-19, the interim final rule with comment period (IFC) is eliminating the requirement for Medicare-Medicaid Plans to submit the HEDIS 2020 data for 2019 measurement year and the 2020 CAHPS survey data.
<b>Action</b>	Informational to PACE.
<b>CMS Memo Title &amp; Release Date</b>	Reminder of Flexibilities for Notice Delivery for Beneficiaries Receiving Institutional Care – Dated 4/2/2020
<b>Summary</b>	CMS remind plans of the flexibilities for notice delivery to beneficiaries receiving institutional care when a beneficiary is being isolated for treatment of suspected or confirmed COVID-19.
<b>Action</b>	Informational to PACE. Refer to the memo for complete details.

**For the latest CMS response to COVID-19, please visit the [CMS.gov](https://www.cms.gov) website.**

**Important Date Reminders**

<b>Date</b>	<b>Item</b>
June 29, 2020 11:59 PM ET	Deadline for 2019 PDE Submissions
June 30, 2020 11:59 PM PT	Deadline for 2019 Direct & Indirect Remuneration (DIR) Submission

*\*Subject to change, forthcoming information to be release by CMS.*

Please note that this information is provided to you in summary form for general informational purposes only and does not constitute legal or regulatory compliance advice. It is your responsibility to consult with your Compliance Officer and/or legal counsel to determine applicability of any regulation or standards referenced herein to your organization and/or processes.